Cargando…

Efficacy and Safety Profile of Combining Vandetanib with Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer: A Meta-Analysis

OBJECTIVE: To evaluate the efficacy and safety profile of combining vandetanib with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). METHODS: MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials (CENTRAL), ASCO Abstracts, ESMO Abstracts, Wanfang Database, CNKI we...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tian, Wei, Ding, Wenping, Kim, Sungkyoung, Zheng, Leizhen, Zhang, Li, Li, Xiaoping, Gu, Jianchun, Zhang, Lian, Pan, Minggui, Chen, Siyu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3701636/ https://www.ncbi.nlm.nih.gov/pubmed/23861835 http://dx.doi.org/10.1371/journal.pone.0067929

Ejemplares similares

Arsenic sulfide inhibits cell migration and invasion of gastric cancer in vitro and in vivo
por: Zhang, Lian, et al.
Publicado: (2015)

Clinical response to sunitinib as a multitargeted tyrosine-kinase inhibitor (TKI) in solid cancers: a review of clinical trials
por: Kim, Sungkyoung, et al.
Publicado: (2014)

Vandetanib
por: Vozniak, J. Michael, et al.
Publicado: (2012)

Arsenic sulfide, the main component of realgar, a traditional Chinese medicine, induces apoptosis of gastric cancer cells in vitro and in vivo
por: Zhang, Lian, et al.
Publicado: (2014)

The survival and the long-term trends of patients with gastric cancer in Shanghai, China
por: Zheng, Leizhen, et al.
Publicado: (2014)

Arsenic sulfide as a potential anti-cancer drug
por: DING, WENPING, et al.
Publicado: (2015)

Apoferritin/Vandetanib Association Is Long-Term Stable But Does Not Improve Pharmacological Properties of Vandetanib
por: Jáklová, Kateřina, et al.
Publicado: (2021)

Arsenic sulfide combined with JQ1, chemotherapy agents, or celecoxib inhibit gastric and colon cancer cell growth
por: Zhang, Lian, et al.
Publicado: (2015)

Study of Arsenic Sulfide in Solid Tumor Cells Reveals Regulation of Nuclear Factors of Activated T-cells by PML and p53
por: Ding, Wenping, et al.
Publicado: (2016)

Prognostic role of HER2 amplification based on fluorescence in situ hybridization (FISH) in pancreatic ductal adenocarcinoma (PDAC): a meta-analysis
por: Li, Xiaoping, et al.
Publicado: (2016)

Safety and activity of vandetanib in combination with everolimus in patients with advanced solid tumors: a phase I study
por: Cascone, T., et al.
Publicado: (2021)

Clinical utility of vandetanib in the treatment of patients with advanced medullary thyroid cancer
por: Deshpande, Hari, et al.
Publicado: (2011)

Stevens-Johnson Syndrome Induced by Vandetanib
por: Yoon, Jimi, et al.
Publicado: (2011)

Radiosensitisation of Hepatocellular Carcinoma Cells by Vandetanib
por: Znati, Sami, et al.
Publicado: (2020)

Vandetanib in Advanced Medullary Thyroid Cancer: Review of Adverse Event Management Strategies
por: Grande, Enrique, et al.
Publicado: (2013)

Vandetanib for the Treatment of Metastatic Medullary Thyroid Cancer
por: Degrauwe, Nils, et al.
Publicado: (2012)

Role of vandetanib in the management of medullary thyroid cancer
por: Brassard, Maryse, et al.
Publicado: (2012)

Selective use of vandetanib in the treatment of thyroid cancer
por: Fallahi, Poupak, et al.
Publicado: (2015)

Dermoscopic findings of perifollicular pigmentation associated with vandetanib
por: Cury-Martins, Jade, et al.
Publicado: (2018)

Investigating the effect of vandetanib and celecoxib combination on angiogenesis
por: Qadir, Abdul, et al.
Publicado: (2023)

Vortex Keratopathy in a Patient Receiving Vandetanib for Non-Small Cell Lung Cancer
por: Ahn, Jeeyun, et al.
Publicado: (2011)

Current status of vandetanib (ZD6474) in the treatment of non-small cell lung cancer
por: Flanigan, Jaclyn, et al.
Publicado: (2010)

Vandetanib for the Management of Advanced Medullary Thyroid Cancer: A Real-World Multicenter Experience
por: Kim, Mijin, et al.
Publicado: (2020)

Vandetanib (ZD6474) in the Treatment of Medullary Thyroid Cancer
por: Deshpande, Hari, et al.
Publicado: (2011)

Efficacy and Safety of Vandetanib in Progressive and Symptomatic Medullary Thyroid Cancer: Post Hoc Analysis From the ZETA Trial
por: Kreissl, Michael C., et al.
Publicado: (2020)

Vandetanib-eluting Radiopaque Beads: In vivo Pharmacokinetics, Safety and Toxicity Evaluation following Swine Liver Embolization
por: Denys, Alban, et al.
Publicado: (2017)

MicroRNA-375/SEC23A as biomarkers of the in vitro efficacy of vandetanib
por: Lassalle, Sandra, et al.
Publicado: (2016)

Photosensitivity Reactions to Vandetanib: Redevelopment after Sequential Treatment with Docetaxel
por: Son, Young-Min, et al.
Publicado: (2011)

Pharmacokinetic Drug Interactions with Vandetanib during Coadministration with Rifampicin or Itraconazole
por: Martin, Paul, et al.
Publicado: (2012)

Long‐term cardiovascular effects of vandetanib and pazopanib in normotensive rats
por: Cooper, Samantha L., et al.
Publicado: (2019)

Vandetanib induced phototoxic reaction progressed to toxic epidermal necrolysis()
por: Gul, Busra Demirbag, et al.
Publicado: (2022)

Ginsenoside Rg3 Alleviates Antithyroid Cancer Drug Vandetanib-Induced QT Interval Prolongation
por: Zhang, Juan, et al.
Publicado: (2021)

Phase I/II Trial of Vandetanib and Bortezomib in Adults with Locally Advanced or Metastatic Medullary Thyroid Cancer
por: Del Rivero, Jaydira, et al.
Publicado: (2018)

Risk of rash associated with vandetanib treatment in non-small-cell lung cancer patients: A meta-analysis of 9 randomized controlled trials
por: Liu, Yuan, et al.
Publicado: (2017)

The multi-targeted tyrosine kinase inhibitor vandetanib plays a bifunctional role in non-small cell lung cancer cells
por: Zhou, Yan, et al.
Publicado: (2015)

A secondary RET mutation in the activation loop conferring resistance to vandetanib
por: Nakaoku, Takashi, et al.
Publicado: (2018)

Evaluating vandetanib in the treatment of medullary thyroid cancer: patient-reported outcomes
por: Fallahi, Poupak, et al.
Publicado: (2019)

Vandetanib Reduces Inflammatory Cytokines and Ameliorates COVID-19 in Infected Mice
por: Puhl, Ana C., et al.
Publicado: (2021)

Vandetanib-Induced Hyponatremia and Torsades De Pointes: A Case Report
por: Ashraf, Shoaib, et al.
Publicado: (2022)

Efficacy and safety of chemotherapy for newly diagnosed advanced non-small cell lung cancer with venous thromboembolism
por: Zhang, Xueli, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_kfmfgnjvu2rdctatkcnu9l6bkl